The oral inhibitor of Lp(a) particle assembly, muvalaplin, significantly reduced elevated Lp(a) levels in adults at high risk of cardiovascular events in the Phase 2 KRAKEN trial presented at AHA 20241 and published simultaneously in JAMA.2
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.